{
    "organizations": [],
    "uuid": "5296bb235bbe223acfb2207e7713177d4dd78b2a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-teva-presents-new-long-term-data-d/brief-teva-presents-new-long-term-data-demonstrating-efficacy-safety-of-copaxone-40-mg-ml-idUSFWN1S41V9",
    "ord_in_thread": 0,
    "title": "BRIEF-Teva Presents New Long-Term Data Demonstrating Efficacy & Safety Of Copaxone 40 Mg/Ml",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 27, 2018 / 7:52 PM / Updated 25 minutes ago BRIEF-Teva Presents New Long-Term Data Demonstrating Efficacy & Safety Of Copaxone 40 Mg/Ml Reuters Staff 1 Min Read\nApril 28 (Reuters) - Teva Pharmaceutical Industries Ltd :\n* TEVA PRESENTS NEW LONG-TERM DATA DEMONSTRATING EFFICACY AND SAFETY OF COPAXONE (GLATIRAMER ACETATE INJECTION) 40 MG/ML\n* TEVA PHARMACEUTICAL INDUSTRIES LTD - NO NEW OR UNEXPECTED ADVERSE EVENTS EMERGED IN PATIENTS RECEIVING COPAXONE 40 MG/ML FOR UP TO 7 YEARS\n* TEVA PHARMACEUTICAL INDUSTRIES LTD - ADVERSE EVENTS WERE GENERALLY MILD AND CONSISTENT WITH WELL-ESTABLISHED SAFETY PROFILE OF COPAXONE Source text for Eikon: Further company coverage:",
    "published": "2018-04-27T22:52:00.000+03:00",
    "crawled": "2018-04-27T23:18:20.014+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "present",
        "new",
        "data",
        "demonstrating",
        "efficacy",
        "safety",
        "copaxone",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "teva",
        "pharmaceutical",
        "industry",
        "ltd",
        "teva",
        "present",
        "new",
        "data",
        "demonstrating",
        "efficacy",
        "safety",
        "copaxone",
        "glatiramer",
        "acetate",
        "injection",
        "teva",
        "pharmaceutical",
        "industry",
        "ltd",
        "new",
        "unexpected",
        "adverse",
        "event",
        "emerged",
        "patient",
        "receiving",
        "copaxone",
        "year",
        "teva",
        "pharmaceutical",
        "industry",
        "ltd",
        "adverse",
        "event",
        "generally",
        "mild",
        "consistent",
        "safety",
        "profile",
        "copaxone",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}